Results 1 to 10 of about 36,741 (290)

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents [PDF]

Pharmacogenomics and Personalized Medicine, 2016
Adem Yesuf Dawed, Kaixin Zhou, Ewan Robert Pearson  Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, Scotland, UK Abstract: Type 2 diabetes is one of the leading causes of morbidity ...
Dawed AY, Zhou K, Pearson ER
doaj   +4 more sources

Re-starting or initiating guideline-recommended hypoglycemic agents for patients admitted with hyperglycemic crisis [PDF]

Frontiers in Medicine
IntroductionHyperglycemic crises, such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), are life-threatening complications of diabetes. This study aimed to assess the impact of early initiation of non-insulin hypoglycemic agents
Abdulrahman I. Alshaya, Abdulrahman I. Alshaya, Abdulrahman I. Alshaya, Haya Al-Yahya, Abdulmajeed Alshehri, Abdulmajeed Alshehri, Abdulmajeed Alshehri, Mohammed Alrashed, Mohammed Alrashed, Mohammed Alrashed, Omar Alshaya, Omar Alshaya, Omar Alshaya, Lama Alfehaid, Lama Alfehaid, Lama Alfehaid, Hisham A. Badreldin, Hisham A. Badreldin, Hisham A. Badreldin   +18 more
doaj   +2 more sources

Oral Hypoglycemic Agents

Primary Care: Clinics in Office Practice, 1977
Oral agents should not be used in the treatment of patients with asymptomatic maturity-onset diabetes. The indication for sulfonylureas is symptomatic maturity-onset diabetes or excessive hyperglycemia--fasting blood sugar over 300 mg per 100 ml--in the elderly patient who cannot or will not take insulin. The use of biguanides cannot be recommended.
Harold Rifkin
  +10 more sources

Continuity and Completeness of Electronic Health Record Data for Patients Treated With Oral Hypoglycemic Agents: Findings From Healthcare Delivery Systems in Taiwan. [PDF]

Front Pharmacol, 2022
Hsu CN, Huang K, Lin FJ, Ou HT, Huang LY, Kuo HC, Wang CC, Toh S.   +7 more
europepmc   +3 more sources

Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study. [PDF]

Diabetes Metab J, 2021
Moon JS, Suh S, Kim SS, Jin HY, Kim JM, Jang MH, Lee KA, Lee JH, Chung SM, Lyu YS, Kim JH, Kim SY, Jang JE, Kim TN, Kim SW, Jeon E, Cho NH, Kim MK, Kim HS, Nam-Goong IS, Kim ES, Chung JO, Cho DH, Lee CW, Kim YI, Chung DJ, Won KC, Kim IJ, Park TS, Kim DK, Shon H.   +30 more
europepmc   +3 more sources

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. [PDF]

Korean J Intern Med, 2017
Moon MK, Hur KY, Ko SH, Park SO, Lee BW, Kim JH, Rhee SY, Kim HJ, Choi KM, Kim NH, Committee of Clinical Practice Guidelines of the Korean Diabetes Association.   +10 more
europepmc   +4 more sources

Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin

Indian Journal of Endocrinology and Metabolism, 2012
Approximately 10% of phenotypic type 2 diabetics have islet autoantibodies and are referred to as having latent autoimmune diabetes of adults (LADA), and they land on early sulfonylurea failure and require insulin.
Resham R Poudel
doaj   +2 more sources

Effects of Short-Term Intensive Insulin Therapy Combined With Oral Hypoglycemic Agents for Inducing Remission in Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Clinical Trial. [PDF]

J Diabetes
Ke W, Liu L, Zhang P, Yan L, Zhang Q, Zhang F, Xu X, Liu J, Xu L, Wan X, Li H, Cao X, Xiao H, Putman MS, Li Y.   +14 more
europepmc   +3 more sources

Oral hypoglycemic agents [PDF]

, 2020
National Diabetes Information Clearinghouse (NDIC)
openaire   +2 more sources

Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice. [PDF]

BMC Endocr Disord, 2017
Hwang YC, Kim A, Jo E, Yang Y, Cho JH, Lee BW.   +5 more
europepmc   +3 more sources